Tectonic Therapeutic (TECX) Cash & Equivalents (2017 - 2026)

Tectonic Therapeutic (TECX) has reported Cash & Equivalents for 10 consecutive years, with $236.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents fell 22.64% year-over-year to $236.9 million; the TTM figure through Mar 2026 stood at $236.9 million (down 22.64% YoY), while the FY2025 annual figure was $253.8 million, up 79.69% from the prior year.
• Cash & Equivalents fell to $236.9 million in Q1 2026 per TECX's latest filing, from $253.8 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $306.2 million in Q1 2025 and bottomed at $6.3 million in Q3 2023.
• Historically, Cash & Equivalents has averaged $146.0 million across 5 years, with a median of $141.2 million in 2024.
• Annual changes were most pronounced in 2023 — Cash & Equivalents plunged 94.54% — and 2024, when it jumped 2413.35%.
• Tectonic Therapeutic's Cash & Equivalents stood at $92.6 million in 2022, then slumped by 68.92% to $28.8 million in 2023, then soared by 390.94% to $141.2 million in 2024, then surged by 79.69% to $253.8 million in 2025, then slipped by 6.66% to $236.9 million in 2026.
• Business Quant data shows TECX's Cash & Equivalents at $236.9 million in Q1 2026, $253.8 million in Q4 2025, and $268.4 million in Q3 2025.